CliffBio
biologic

Neupogen

filgrastim

Loss of exclusivityJune 2012projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameNeupogen
Active ingredientfilgrastim
Strength300MCG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2000
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Neupogen patent cliff — loss of exclusivity June 2012 | CliffBio